Detalles de la búsqueda
1.
Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.
Int J Clin Oncol
; 26(11): 2131-2141, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34363558
2.
Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
BMC Cancer
; 19(1): 578, 2019 Jun 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31195996
3.
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
Breast Cancer Res Treat
; 146(2): 321-8, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24699910
4.
Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.
BMC Cancer
; 14: 69, 2014 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-24498872
5.
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study.
Breast Cancer (Dove Med Press)
; 8: 231-239, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27994483
6.
Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.
Clin Breast Cancer
; 16(1): 31-7, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26433876
7.
Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer.
Am J Health Syst Pharm
; 72(24): 2150-6, 2015 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26637514
8.
Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies.
Springerplus
; 4: 532, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26413438
9.
Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
J Blood Med
; 6: 25-9, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25678833
10.
Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia.
Leuk Res Rep
; 3(1): 17-20, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24596676
11.
A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
Clin Lymphoma Myeloma Leuk
; 14(1): 68-72, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24220616
12.
Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
Clin Breast Cancer
; 14(6): 405-12, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25024001
Resultados
1 -
12
de 12
1
Próxima >
>>